The Medicines Co. Enters PCSK9 Race With Alnylam Deal

This article was originally published in The Pink Sheet Daily

04 Feb 2013
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Deals
Clinical Trials

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Deals Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS075342

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS075342

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

The Medicines Co. Enters PCSK9 Race With Alnylam Deal

News

Executive Summary

Related Content

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert